【摘要】 目的:探讨瑞舒伐他汀对急性冠脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)术后支架内再狭窄的预防作用。方法:回顾性选取我院2014年6月～2018年6月收治的106例ACS患者纳入本研究,将入选患者依据随机数字表法分成阿托组与瑞舒组(n=53)。两组患者均给予常规治疗,阿托组患者在此基础上给予阿托伐他汀治疗,瑞舒组患者在此基础上给予瑞舒伐他汀治疗。PCI术后随访6个月。观察两组患者术前、随访时的血脂指标、血清指标、支架内最小管腔内径(MLD)的变化。结果:治疗后,两组患者血脂指标、血清指标均较治疗前有所改善,且瑞舒组均优于阿托组,均有统计学差异(P<0. 05)。PCI术后6个月,瑞舒组MLD大于阿托组,瑞舒组支架内再狭窄发生率低于阿托组,均有统计学差异(P<0. 05)。结论:瑞舒伐他汀能够有效降低ACS患者PCI术后支架内再狭窄发生率,并调节患者血脂水平与炎症反应。更多还原

【Abstract】 Objective:To investigate the preventive effect of rosuvastatin on stent restenosis after percutaneous coronary intervention(PCI) for acute coronary syndrome(ACS).Methods:106 patients with acute coronary syndrome(ACS) admitted to the hospital from June 2014 to June 2018 were included in this study.Patients were divided into atorvastatin group and rosuvastatin group according to random number table method(n=53).Both groups were given conventional treatment,atorvastatin group with additional atorvastatin on that basis and rosuvastatin group with additional rosuvastatin.All patients were given 6 months follow-up after PCI.The changes of serum lipid index,serum index and minimum lumen diameter(MLD) were analyzed.Results:After treatment,the serum lipid and serum indexes of the two groups were improved compared with before treatment,with more improvement observed in the rosuvastatin group than in the atorvastatin group(P <0.05).Six months after the operation,the MLD in the rosuvastatin group was larger that in the atorvastatin group(P <0.05).The incidence of in-stent restenosis 6 months after PCI in the rosuvastatin group was lower than that in the atorvastatin group(P <0.05).Conclusion:rosuvastatin can effectively reduce in-stent restenosis after PCI treatment of acute coronary syndrome,and regulate patients’ blood lipid level and inflammatory response.更多还原